Swiss Lions rankings | 2026 edition
Idorsia
Idorsia is No. 12 in the Pharma and Biotech ranking, with a score of 21.0 out of 100. It is not among the Swiss Lions 100 for 2026. Registered office: Allschwil, canton of Basel-Landschaft.
- Swiss Lions score
- 21.0
- Swiss Lions 100
- Not in the 100 for 2026
- Pharma and Biotech
- 12of 15
About
Allschwil-based biopharmaceutical company that discovers, develops and sells medicines, including the insomnia treatment QUVIVIQ and the hypertension drug TRYVIO, created in 2017 from Actelion's demerger.
Idorsia researches, develops and commercialises prescription medicines. Its main marketed product is QUVIVIQ (daridorexant) for insomnia, available in the United States and several European countries, whose net sales more than doubled to CHF 134 million in 2025. It also markets aprocitentan for hypertension, sold as TRYVIO in the United States and approved as JERAYGO in the EU, the UK, Switzerland and Canada. Its pipeline includes lucerastat for Fabry disease and immunology assets. Idorsia began operations in 2017, when Actelion's drug discovery activities and early clinical assets were demerged after Johnson & Johnson acquired Actelion. It is headquartered in Allschwil, near Basel, and listed on the SIX Swiss Exchange.
- QUVIVIQ (daridorexant) for insomnia
- TRYVIO / JERAYGO (aprocitentan) for hypertension
- Lucerastat for Fabry disease
- Immunology pipeline (CCR6 antagonist)
Links
How the score is made
Global scale
CHF 221m revenue.
Swiss value
Limited Swiss production.
Global visibility
Online attention across languages, and worldwide search interest.
Impact
No current SBTi target. Not a certified B Corp.
Philanthropy
No charitable foundation found.
Impact and philanthropy together make up the impact measure. How the ranking works.
Key figures
- Revenue used in the ranking
- CHF 221m2025, company
Shares and listing
- Stock exchange
- SIX Swiss ExchangeTicker IDIA
- ISIN
- CH0363463438
- Market value
- CHF 1.1 billionAt the close on 23 October 2026. Source: stockanalysis.com.
- Free float
- 71.8%Shares not held by large long-term shareholders. Source: simplywall.st.
Profit, dividends and employee numbers are published in the company's annual report.
We have not found a published figure for employees in Switzerland for 2025 or 2026, and dividends paid to Swiss shareholders are not published, so neither is shown.
Profile
- Registered office
- AllschwilCanton of Basel-Landschaft
- Language region
- German-speaking
- Category
- Pharma and Biotech
- Ownership
- Listed, no controlling shareholder
- Chief executive
- Jean-Paul ClozelSince 2026. Source
- Chair
- Jean-Paul ClozelSource
- Formed
- 2017Spin-off from Actelion
In Switzerland
- Allschwil BLHeadquarters
Over time
| Year | Revenue | Employees |
|---|---|---|
| 2025 | CHF 221m | 487 |
| 2024 | CHF 113m | 689 |
| 2023 | CHF 152m | – |
| 2022 | CHF 97m | – |
As reported by the company, in its own reporting currency.
Milestones
- 2017Begins operations after demerging from Actelion following its acquisition by Johnson & Johnson.
- 2022QUVIVIQ becomes commercially available in the United States.
- 2024US FDA approves TRYVIO for hypertension.
- 2026Srishti Gupta steps down; chairman Jean-Paul Clozel becomes interim CEO.
Also in Pharma and Biotech
1RocheScore 77.3
2NovartisScore 75.3
3LonzaScore 56.3
4SandozScore 52.1
5FerringScore 49.8
6SiegfriedScore 44.1
See all 15 brands in Pharma and Biotech. Read the 2026 data story for Pharma and Biotech.
Sources
- Revenue used in the ranking: biospace.com (2025).
- Company profile, sites, history and milestones: biospace.com, globenewswire.com, idorsia.com.
- Climate target: Science Based Targets initiative dashboard, status at 30 June 2026. Foundations: Swiss commercial register. B Corp: B Lab directory.
Something out of date?
If a figure is wrong, or Idorsia can publish figures for the next edition, tell us. Corrections are recorded with their source.